Louise Frederika Kooij Sells 105,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 105,000 shares of the business’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $30.34, for a total value of $3,185,700.00. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at approximately $738,870.02. This trade represents a 81.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Monday, June 22nd, Louise Frederika Kooij sold 40,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $30.20, for a total transaction of $1,208,000.00.
• On Tuesday, May 26th, Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.69, for a total value of $2,319,850.00.

NewAmsterdam Pharma Price Performance

NAMS traded down $1.71 during midday trading on Tuesday, reaching $28.51. 145,258 shares of the company’s stock traded hands, compared to its average volume of 1,021,799. NewAmsterdam Pharma Company N.V. has a 52 week low of $21.14 and a 52 week high of $42.21. The firm has a fifty day moving average of $32.73 and a two-hundred day moving average of $32.84. The stock has a market capitalization of $3.33 billion, a price-to-earnings ratio of -15.97 and a beta of 0.08.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. The business had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. Sell-side analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current year.

Institutional Investors Weigh In On NewAmsterdam Pharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Swedbank AB bought a new position in NewAmsterdam Pharma in the 4th quarter valued at approximately $3,189,000. Legato Capital Management LLC raised its stake in shares of NewAmsterdam Pharma by 258.7% in the fourth quarter. Legato Capital Management LLC now owns 83,833 shares of the company’s stock worth $2,941,000 after purchasing an additional 60,463 shares during the last quarter. UBS Group AG raised its stake in shares of NewAmsterdam Pharma by 17.0% in the fourth quarter. UBS Group AG now owns 899,442 shares of the company’s stock worth $31,552,000 after purchasing an additional 130,922 shares during the last quarter. JTC Employer Solutions Trustee Ltd bought a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at $2,649,000. Finally, Aberdeen Group plc lifted its holdings in shares of NewAmsterdam Pharma by 10.2% during the fourth quarter. Aberdeen Group plc now owns 729,484 shares of the company’s stock valued at $25,590,000 after purchasing an additional 67,538 shares in the last quarter. Institutional investors own 89.89% of the company’s stock.

Analyst Ratings Changes

NAMS has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. Royal Bank Of Canada increased their target price on NewAmsterdam Pharma from $47.00 to $51.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 30th. BMO Capital Markets assumed coverage on NewAmsterdam Pharma in a research report on Monday, July 20th. They set an “outperform” rating and a $58.00 price target on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $45.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Finally, Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $49.42.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.